September 4, 2024
Wonderful to be named as a 2024 finalist in the EIT Health Catapult Competition. From 100s of companies considered ➡️ to 30 semi-finalists ➡️ to the […]
September 4, 2024
January 24, 2024
London, UK – 24 January 2024. A clinical validation study of Digistain in 801 patients with ER-positive, HER2-negative early breast cancer (median follow-up 12.7 years) was […]
October 12, 2023
We are the finalists of Health Tech Challengers 2023. Join us at the event
October 11, 2023
We take pride in our involvement with SpinOff Bulgaria, a program dedicated to nurturing innovation and promoting entrepreneurial spirit.
September 13, 2023
Delighted to have been selected by EIT Health as a semi-finalist.
May 11, 2023
We are presenting a poster at the ESMO Breast Cancer Annual Congress (#ESMOBreast23) from 11-13 May in Berlin. The poster reports the prognostic performance of the […]
April 30, 2023
Team Digistain with Prof Sir Mike Dixon OBE at the American Society of Breast Surgeons Annual Symposium this year where we were honored to be selected […]
March 1, 2023
Honoured today to be offered a place on NHS Oxford’s UK Access Program! #digitalhealth #accelerator